HDAC9 and non-small cell lung carcinoma: In addition, studies investigating HDAC inhibition in combination with immunomodulatory treatments in patients with advanced colorectal cancer, genitourinary cancers, melanoma, uveal melanoma, or NSCLC are ongoing (29–33).